Skip to main content

Remote Job Finders (RJF)

Is Revolution ‘the next oncology titan’? Truist analysts make the case

A month after reporting that its RAS inhibitor daraxonrasib doubled survival in advanced pancreatic cancer, Truist said Revolution Medicines “is evolving into a major revenue-generating oncology company,” and projects an approval in second-line disease by the end of the third quarter.

Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B

Right after reporting a major Phase 3 LAG-3 miss that has rattled analysts, Regeneron Pharmaceuticals revealed a back-loaded partnership with Parabilis Medicines aimed at adding a new drug class to its early-stage pipeline.

Employment and funding growth fell in 2025: California Life Sciences report

California life sciences jobs declined 1.8% last year, according to the new California Life Sciences sector report. While National Institutes of Health funding and venture capital investment rose, their growth slowed from the previous year.

Degron adds $40M to series A, supporting immunology plans for molecular glue platform

Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-mediated conditions.

Hiring outlook: job opportunities on BioSpace rise YOY, but layoffs affect thousands

While average job postings live on BioSpace have increased year over year for nearly every month of 2026, the number of employees affected by made or planned layoffs by the end of that same period nearly matched what was seen in 2025.
Scroll to top